Clinical trial
Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years.
NCT01532856 is registered in ClinicalTrials.gov with Grupo de Estudos Multicentricos em Onco-Hematologia as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years.
- Lead sponsor
- Grupo de Estudos Multicentricos em Onco-Hematologia
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2007
- Completion date
- June 30, 2012
- Enrollment
- 64 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.